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 Introduction 
 Hyperostosis frontalis interna (HFI) is a thickening of 
the inner table of the frontal bone. It is mainly diagnosed 
in elderly women and is an age-dependent process. In a 
population of European American females, studied by 
Hershkovitz et al.  [1] , 8–19% of over 70-year-old women 
showed advanced HFI. The pathogenesis remains un-
clear; some authors believe HFI to be caused by increased 
leptin levels or prolonged estrogen stimulation  [1–3] . 
 HFI may occur as an independent entity. However, it 
is often associated with other conditions and may be part 
of several syndromes such as the Morgagni-Stewart-Mo-
rel (MSM) syndrome, the most current features of which 
are HFI, obesity, hirsutism and neuropsychiatric or met-
abolic disorders like diabetes mellitus.  
 In this case report, we present two monozygotic twins 
suffering from marked HFI, generalized seizures, cogni-
tive impairment, obesity and shortness, suggesting a
genetic background of this symptom complex. In addi-
tion to these common disturbances, the patients show 
some interindividually differing features demonstrat-
ing phenotypic variability in these genetically identical 
twins. 
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 Abstract 
 We report two 71-year-old female monozygotic twins 
presenting with advanced hyperostosis frontalis interna, 
obesity, shortness and cognitive impairment. They both 
have suffered from generalized seizures since their early 
adulthood. Moreover, the patients showed some addi-
tional conditions only occurring in one individual or the 
other such as migraine, marked recurrent depressive dis-
order or polyarthrosis. The symptoms common to both 
twins appear to correspond to the Morgagni-Stewart-
Morel syndrome and indicate a genetic basis of this dis-
order as these features occur in genetically identical pa-
tients. 
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 Case Reports 
 The index subject (twin 1), a 71-year-old widowed mother of 
one daughter, was admitted to the Inpatient Unit of the Division 
of Psychiatry Research, Psychiatric University Hospital Zurich, 
with dementia accompanied by behavioral symptoms such as ag-
gression and confusion. Symptoms of dementia had evolved over 
the preceding 9 years. The patient had suffered from epilepsy with 
generalized tonic-clonic seizures since the age of 15 years. Anticon-
vulsive treatment with phenobarbital was initiated at the age of 27 
and continued until the present. At the age of 51, valproic acid was 
added. Upon admission, the patient received phenobarbital 
(100 mg/day), valproic acid (800 mg/day) and olanzapine (15 mg/
day), the latter because of behavioral abnormalities. She had been 
seizure free over the past 5 years. Physical examination showed 
obesity (74.5 kg, 144 cm, body mass index, BMI, 35.9) and dysmor-
phic features. The ﬁ ndings of the examination of the cardiovascular 
system were unremarkable. There were no focal neurological signs 
and symptoms. The patient suffered from polyarthrosis, psoriasis, 
prurigo and urine incontinence. Hematological examination and 
urine analysis were normal. Blood chemistry and hormone testing 
showed hyperprolactinemia, hyperlipidemia and slight hyperglyce-
 Fig. 1. Cranial MRI scans from twin 1 ( a ,  b ) and cranial open MRI scans from twin 2 ( c ,  d ).  a ,  c Axial T 2 -weight-
ed MRI scans with gadolinium.  b ,  d Sagittal T 1 -weighted MRI scans.  a ,  b Bilateral thickening of the inner layer of 
the frontal bone with oppression of the forebrain. White matter lesions, predominantly in the frontal lobe. Moder-
ate cortical atrophy.  c ,  d Bilateral thickening of the inner layer of the frontal bone, no clear cortical atrophy. 
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mia. Anti- Borrelia antibodies and  Treponema  pallidum testing 
were negative. Normal blood concentrations were obtained for vi-
tamin B 12 , folate, free T 3 , free T 4 , cortisol, testosterone, free testos-
terone, dihydrotestosterone, androstenedione and dehydroepi-
androsterone sulfate. Cerebrospinal ﬂ uid examination showed 
slightly increased liquor pressure (18 cm H 2 O) but was otherwise 
normal. EEG was abnormal with increased delta wave activity and 
seizure-associated sporadic bifrontal spike activity. Cranial mag-
netic resonance imaging (MRI;  ﬁ g. 1 a, b) revealed symmetric thick-
ening of the inner table of the frontal bone, generalized cerebral 
atrophy and moderate vascular white-matter lesions. The patient 
was in an affectively labile state but not depressed (Montgomery 
Asberg Depression Scale, MADRS, 9/60)  [4] . She showed mark-
edly impaired cognitive performance (Mini Mental State Examina-
tion, MMSE, 16/30)  [5] . Neuropsychological assessment using the 
CERAD test battery  [6] yielded a severe impairment of verbal and 
nonverbal learning and retrieval, extremely weak lexical and asso-
ciative semantic memory and massively reduced executive func-
tions (verbal and nonverbal ﬂ uency, conceptual thinking and cog-
nitive ﬂ exibility). The patient was not properly oriented with re-
spect to time, place, situation and to herself. Moreover, she 
exhibited dyscalculia, dyslexia and mild difﬁ culties in language 
comprehension. There were also signs of a visual apperceptive ag-
nosia. These impairments clearly exceeded those commonly ob-
served in relation to epilepsy or phenobarbital intake  [7, 8] and 
were rather indicative of moderate dementia according to the 
DSM-IV criteria (Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition). After admission, phenobarbital and olanzap-
ine were discontinued, valproic acid was increased to 1,000 mg/
day. This change in pharmacotherapy management led to a marked 
amelioration of the confusional state and of the aggressive behav-
ior. Dementia, however, persisted unchanged, and the patient had 
to be discharged into a nursing-home. 
 The index patient’s twin sister (twin 2), a married mother of 
three healthy children, was recruited at the same time for ambulant 
clinical examination. She reported a similar medical history as her 
sister with generalized epileptic seizures since the age of 18. She had 
been treated with anticonvulsants since the age of 27. At the time 
of this examination, she was receiving phenobarbital at 100 mg/day 
and valproic acid at 800 mg/day and had been free of seizures for 
the past 4 years. A standard EEG recorded 2 years before this ex-
amination failed to reveal epileptic activity. In her thirties, the pa-
tient developed recurrent depressive disorder leading to psychiatric 
hospitalization, and in her forties she developed frontal migraine-
like headaches. The current physical examination showed obesity 
(60 kg, 141.5 cm, BMI 30.0) but was otherwise normal. She showed 
some moderate behavioral symptoms such as disinhibition and log-
orrhea typically observed along with prefrontal dysfunctions, but no 
signs of depression (MADRS 8/60)  [4] . Her cognitive abilities were 
impaired with an MMSE score of 21/30  [5] . She was fully oriented. 
The neuropsychological assessment (CERAD battery)  [6] revealed 
discrete difﬁ culties with nonverbal episodic memory. Yet, verbal 
episodic memory was normal.  Regarding executive functions, she 
exhibited mildly reduced conceptual thinking abilities and a more 
clearly reduced verbal and nonverbal ﬂ uency. Her visuoconstruc-
tive abilities were also mildly diminished. This pattern of dysfunc-
tion and the progression of these symptoms were suggestive of be-
ginning dementia. Cranial MRI ( ﬁ g. 1 c, d) showed bilateral HFI but 
no clear brain atrophy. Hematology, blood chemistry and urine 
analysis were normal; hormone levels were not determined.  
 The twins’ parents, two sisters (83 years, 82 years) and one 
brother (60 years) were reported free of epilepsy. The index pa-
tient’s daughter (35 years) has suffered from generalized seizures 
since early adulthood. The twin sister’s children (a son 50 years of 
age, two daughters 49 and 46 years of age) were reported healthy. 
In the distant maternal lineage, two members are known to have 
suffered from seizures. In the father’s family, no epileptic disorders 
are known.  
 To assess whether the twin sisters are genetically identical, a 
DNA proﬁ le for determination of monozygosity was done. Exami-
nation of 17 highly polymorphic DNA markers (D3S1358, TH01, 
D21S11, D18S51, Penta E, D5S818, D13S317, D7S820, D16S539, 
CSF1P0, Penta D, VWA, D8S1179, TPOX, FGA, D2S1338, 
D19S433) showed that the sisters were monozygotic twins  [9, 10] . 
 Discussion 
 We report advanced HFI accompanied by generalized 
seizures, obesity, shortness and cognitive impairment in 
71-year-old female monozygotic twins. The index patient 
(twin 1) was admitted to the Psychiatric University Hos-
pital Zurich for an inpatient investigation and treatment 
of dementia, aggressivity and confusion. Twin 2 was in-
vited for an ambulant examination at the same time as 
her sister was hospitalized which allowed us to make a 
comparison between these two genetically identical sis-
ters.  
 The sisters have suffered from generalized seizures 
and have received anticonvulsive medication since their 
early adulthood. They have been free of seizures for sev-
eral years. Epilepsy has been reported to occur in several 
female members of the maternal line of the family sug-
gestive of a genetic basis of the seizures. Yet, we are not 
able to describe the mode of transmission. 
 HFI and obesity were more pronounced in twin 1 than 
in twin 2 ( table 1 ). The index patient was moderately de-
mented with cerebral atrophy and showed frontal dys-
functions as shown in the neuropsychological assessment. 
Moreover, she displayed dysmorphic features, polyar-
throsis, psoriasis, hyperprolactinemia, hyperlipidemia 
and slight hyperglycemia. Upon changing medication, 
behavioral abnormalities such as aggressivity and confu-
sion decreased while dementia persisted. Therefore, she 
had to be discharged from hospital to a nursing-home. 
Neuropsychological assessment of her sister revealed only 
mild dementia with diminished executive functions, epi-
sodic memory and visuoconstructive skills. The sister 
 exhibited no cerebral atrophy. She has suffered from 
 migraine and marked recurrent depressive disorder for 
decades. Altogether, the inpatient was physically and 
mentally more impaired than her sister, despite their ge-
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netical identity. The reason for the phenotypic variabil-
ity may lie either in different environmental factors such 
as lifestyle or nutrition, in mosaicism occurring in mono-
zygotic twins or in a more complex polygenetic etiology. 
Unfortunately, we do not know about HFI and the other 
features mentioned above in the family members as we 
did not have the opportunity to examine them. The neu-
ropsychological assessments of the twins indicative of 
prefrontal dysfunctions are in line with the literature of 
prefrontal dysfunctions. These might be a consequence 
of the compression of the prefrontal cortex by the thick-
ening frontal bone in HFI  [11, 12] . If HFI is also the rea-
son for dementia remains unclear since – to our knowl-
edge – such a relationship has never been observed. Nei-
ther are epilepsy or the antiepileptic treatment  [7, 8] 
reasonable causes of dementia. Instead, we believe that 
dementia and the other symptoms in our twins are part 
of an MSM syndrome – a syndrome with a controversial 
history. 
 HFI was ﬁ rst described by Morgagni in the 18th cen-
tury in an elderly obese and virilized woman  [13] . This 
ﬁ rst report was followed by numerous further publica-
tions on this condition where HFI was both described as 
an independent entity and as part of a syndrome includ-
ing obesity, hirsutism and metabolic or neuropsychiatric 
disorders like seizures. The terminology of the syndrome 
is variable: it has been referred to as MSM syndrome, 
metabolic craniopathy, Morel-Moore syndrome etc. The 
deﬁ nition of the syndrome remains nonuniform both due 
to the diversity of the reported associated symptoms and 
to the variable penetrance of the condition; not all symp-
toms have to be present for the diagnosis of the syndrome; 
e.g. signs of hirsutism have often been reported to be very 
mild or even absent  [14, 15] – as in our patients. Some 
authors  [1, 2] doubt the existence of the syndrome sui 
generis because certain symptoms of the MSM syndrome 
may occur as independent entities in elderly women and 
because the syndrome is ill deﬁ ned. These authors claim 
that the combination of the symptoms is accidental. This 
notion is not consistent with the ﬁ rst signs of the syn-
drome being present at the age of puberty. Also, it con-
ﬂ icts with the ﬁ ndings of numerous authors who observed 
the symptom complex in several members of a single fam-
ily. Klein et al.  [15] and Rosatti  [16] examined an affect-
ed family over four generations and postulated an auto-
somal-dominant or X-linked mode of inheritance with 
variable and incomplete penetrance. The existence of a 
hereditary syndrome is supported by its occurrence in 
monozygotic twins, such as reported here. The coinci-
dence of the conspicuous conditions in our twins is un-
likely to be accidental because some of the observed fea-
tures are infrequent, e.g. familial seizures, advanced HFI 
which only occurs in 8–19% of women over 70 years old 
 [1] , a BMI of over 30 which is found in only 10% of Swiss 
females between 35 and 74 years  [17] and a body height 
of less than 145 cm which is far below the mean of the 
Swiss female height standard of 165 cm (SD 6 cm)  [18] . 
It is hard to say whether the seizures appeared as part of 
the MSM syndrome or as a nonassociated second hered-
itary illness. Anyhow, seizures have been described as 
part of the MSM syndrome  [16] . The same goes for hy-
perprolactinemia, as observed in twin 1, which may both 
be a symptom of the MSM syndrome and a side effect of 
olanzapine, an antipsychotic twin 1 was treated with. 
 To summarize, this case report adds evidence for the 
validity of the MSM syndrome and for its inheritance 
with an incomplete penetrance.  
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Table 1. Pathological features
Twin 1 Twin 2
HFI +++ ++
Obesity +++ ++
Generalized epilepsy +++ +++
Cognitive impairment ++ +
Frontal dysfunctions +++ ++
Cortical atrophy ++ –
Shortness ++ ++
Recurrent depressive disorder – ++
Migraine – ++
Dysmorphic features ++ –
Polyarthrosis ++ –
Metabolic disorders + –
Semiquantitative estimates: – = absent; + = mild; ++ = marked; 
+++ = severe.
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